Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursd.....»»

Category: europeSource: fortuneOct 11th, 2018

Brainstorm Health: Allogene IPO, Medtronic Hack Concern, Pharmacy Gag Clause

Brainstorm Health Daily: October 11, 2018 Good afternoon, readers--This is Sy. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled .....»»

Category: europeSource: fortuneOct 11th, 2018

Biotech firm raises $54M to hunt for cancer drugs

Gotham Therapeutics, a Manhattan-based biotech company, has received $54 million in Series A financing to advance research into a novel method of finding oncology drug candidates. The research was... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkOct 10th, 2018

Biotech developing cancer drugs kicks off $13M round with $5K pitch contest win

Rockville-based biotechnology company Remedy Plan Therapeutics took home $5,000 Thursday as the winner of the Maryland Tech Council's inaugural Bio+Tech18 pitch competition. That money will go toward a larger, $13 million round the company is looking .....»»

Category: topSource: bizjournalsSep 21st, 2018

Pediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPO

Pediatric cancer biot.....»»

Category: topSource: marketwatchSep 21st, 2018

This cancer-fighting biotech sped from startup to IPO filing in 10 months

The team that took Kite Pharma from a startup re-engineering a patient's own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie B.....»»

Category: topSource: bizjournalsSep 17th, 2018

RiverVest leads $40 million venture capital deal

Clayton-based venture capital firm RiverVest Venture Partners has led a $40 million Series B financing round for a Seattle-based biotech company.  The company, OncoResponse, is developing a portfolio of antibodies to high-value targets for cancer t.....»»

Category: topSource: bizjournalsSep 11th, 2018

Two more Peninsula IPOs tell the story of biotech"s investment boom

And then there were 15. Two Bay Area biotech companies — one that started its first clinical trial in eye diseases in July, the other a pioneer in the fledgling field of hunting down cancer via a simple blood draw — seek to raise $100 million eac.....»»

Category: topSource: bizjournalsSep 8th, 2018

Cancer-fighting startup lands nearly $19 million as Texas hands out more grants to combat disease

Forbius, a company developing drugs to fight cancer, has scored $18.5 million from the state of Texas to advance its pharmaceuticals. The business operates legally as Formation Biologics Corp. and was founded in Montreal, Canada, in 2011 as a spinoff.....»»

Category: topSource: bizjournalsAug 28th, 2018

This Biotech Just Had a $903 Million IPO—And It’s Disappointed

Cancer drug maker BeiGene was looking to score $1 billion in its secondary listing in Hon.....»»

Category: europeSource: fortuneAug 2nd, 2018

Chinese investors lead another monster round for Menlo Park early cancer detection unicorn

Looking to detect cancer early through a simple blood test, Grail Inc. scored $300 million in new funding from several Chinese investors on top of the $1.2 billion it raised over the past two years. The Menlo Park company, which was rumored to be .....»»

Category: topSource: bizjournalsMay 22nd, 2018

Chinese Drugmaker"s IPO Tests a Slumping Biotech Market

A Chinese cancer drug developer is pushing ahead with an initial public offering in Hong Kong, despite a global markets rout and the recent poor performance of other biotechnology startups that have listed in the city......»»

Category: smallbizSource: wsj8 hr. 3 min. ago

The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 11) read more.....»»

Category: blogSource: benzingaOct 12th, 2018

Biotech Equillinium raises about $65.4 million in IPO

Biotech Equillinium Inc. priced its initial publ.....»»

Category: topSource: marketwatchOct 12th, 2018

Judge may order new trial in Roundup case where jury awarded $289 million to cancer-stricken man

A San Francisco judge is considering tossing out mo.....»»

Category: topSource: latimesOct 11th, 2018

How Compugen Is Weathering Thursday’s Storm

Compugen shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb will make a $12 million equity investment as part of its collaboration on a cancer trial......»»

Category: blogSource: 247wallstOct 11th, 2018

Compugen"s stock shoots up after Bristol-Myers to pay 52% premium for equity stake

Shares of Compugen Ltd. shot up 17% in premarket trade Thursday, after Bristol-Myers Squibb Co. said it will make a $12 million equity investment as part of a collaboration on a cancer tre.....»»

Category: topSource: marketwatchOct 11th, 2018

Bayer lifted by likely new trial in $250 million weedkiller case

The prospect of a fresh trial that could overturn $250 million damages against Bayer's Monsanto unit lifted the German company's shares, after an August ruling that it failed to warn users of the alleged cancer risks of its weedkillers......»»

Category: topSource: reutersOct 11th, 2018

Bayer gets tentative ruling for new trial in weed-killer case

Bayer AG's Monsanto unit received a tentative ruling for a new trial on the $250 million in punitive damages awarded by a jury to a groundskeeper who alleged the company's glyphosate-based weed killers, including Roundup, caused his cancer......»»

Category: topSource: reutersOct 10th, 2018

Judge to order new trial in Roundup case where jury awarded $289 million to cancer-stricken man

A San Francisco judge said in a tentative.....»»

Category: topSource: latimesOct 10th, 2018

California judge says she will order a new trial for cancer-stricken man awarded $289 million in Roundup case

California judge says she will order a new trial for cancer-stricken man awarded $289 million in Roundup case......»»

Category: topSource: foxnewsOct 10th, 2018